Altimmune reports pemvidutide Phase 1b MASLD data: LFC reduced up to 68.5%

Altimmune, Inc.

Pemvidutide reduced liver fat content (LFC) by up to 68.5% from baseline over 12 weeks in 94 MASLD patients.
Total cholesterol decreased by up to 12.2% and triglycerides by up to 44.6% after 12 weeks of treatment.
Presented at AASLD The Liver Meeting from a 12-week Phase 1b trial in overweight/obese MASLD subjects.
Subjects received once-weekly subcutaneous pemvidutide (1.2mg, 1.8mg, 2.4mg) or placebo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.